Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis

Cost Effectiveness and Resource Allocation

Research

Wei Wang¹  Horst Buxmann²  Wolfgang Greiner³  Anna-Janina Stephan⁴  Agnes Luzak⁴  Regine Wölle⁴  Marion de Lepper⁵  Rangmar Goelz⁶  Kim Maren Schneider⁷  Christian Jacob⁷  Miriam Reuschenbach⁸  Klaus Hamprecht⁹  Susanne Modrow^1,10  Peter Kummer^1,11 

[1] Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, USA;Department for Children and Adolescents, Division for Neonatology, Main-Kinzig-Kliniken GmbH, Gelnhausen, Germany;Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Bielefeld, Germany;Department of Market Access, MSD Sharp & Dohme GmbH, Munich, Germany;Department of Medical Affairs, MSD Sharp & Dohme GmbH, Munich, Germany;Department of Neonatology, University Children’s Hospital, Tuebingen, Germany;EU Real World Evidence, Xcenda GmbH, Hannover, Germany;Global Medical and Scientific Affairs, MSD Sharp & Dohme GmbH, Munich, Germany;Institute for Medical Virology and Epidemiology of Viral Diseases, University of Tuebingen, Tuebingen, Germany;Institute of Medical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany;Section of Phoniatrics and Pediatric Audiology, Department of Otolaryngology, University Hospital Regensburg, Regensburg, Germany;

关键词: Congenital CMV infection;    Newborns;    Health economic burden;    Germany;    Administrative data;   

DOI  :  10.1186/s12962-022-00411-x

 received in 2022-07-22, accepted in 2022-12-16,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundCongenital cytomegalovirus (cCMV) infection can cause severe neurological damage, growth retardation, hearing loss, and microcephaly in infants. We aimed at assessing healthcare costs of infants with recorded cCMV diagnosis in an administrative claims database in the first 2 years of life.MethodsWe conducted a retrospective, controlled cohort study using German claims data from the Institute for Applied Health Research Berlin (InGef) database. Incremental healthcare costs during the first and second year of life were assessed by matching (1:60) infants with cCMV diagnoses ≤ 90 days after birth (cCMV90 cohort) to infants without cCMV diagnosis (“representative” controls) and infants with cCMV diagnoses ≤ 21 days after birth plus specific symptoms (cCMV21-S) to infants without cCMV and any ICD-10-GM records (besides Z00-Z99) until 4th preventive health check-up (“healthy” controls). Due to missing data, mean imputation was applied for aids and remedies costs.ResultsWe identified 54 and 24 infants born 2014–2018 for the cCMV90 and cCMV21-S cohorts, respectively. During the first year, mean (median) healthcare costs were significantly higher in cCMV90 cases vs. “representative” controls (€22,737 (€9759) vs. €3091 (€863), p < 0.001), with 87.2% inpatient costs. Healthcare costs for cCMV21-S cases compared to “healthy” controls were €34,498 (€20,924) vs. €680 (€569), p < 0.001. Differences decreased for both comparisons in the second year but remained statistically significant.ConclusionscCMV comprises a considerable economic burden for the German healthcare system (€19,646 to €33,818 higher mean costs for infants with recorded cCMV diagnosis in the first year of life). Attempts should be made to reduce this burden.

【 授权许可】

CC BY   
© © Merck & Co., Inc., Rahway, NJ, USA and its affiliates 2023 2023

【 图 表 】

41116_2022_35_Article_IEq40.gif

41116_2022_35_Article_IEq38.gif

Fig. 5

41116_2022_35_Article_IEq36.gif

41116_2022_35_Article_IEq29.gif